Takeda rare disease drug is under FDA investigation following a patient death and reports of neutralizing antibodies.
Author: PharmaSignal News Desk
Novartis job cuts affect hundreds in Swiss manufacturing, while Novo’s diabetes drug advances to Phase 3 trials.
Otsuka FDA approval marks a first for anti-APRIL therapy targeting IgA nephropathy, potentially impacting the rare kidney disease market.
Medicare price negotiation reduces costs by 44% for Wegovy, Trelegy, and 13 other drugs by 2027.
Big Pharma CEO ratings reveal which leaders earn the highest employee approval, impacting company performance and satisfaction.
Kelun Merck ADC shows promise in lung cancer treatment, succeeding in a late-stage trial with potential for first-line approval.
Bayer Asundexian trial results indicate potential for a new class of cardiovascular drugs in stroke prevention.
Novo Nordisk GLP-1 drug fails in Alzheimer’s trials, impacting potential neurodegeneration treatment.
Takeda rare disease drug is under FDA review following a patient death and reports of neutralizing antibodies.
In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, significant M&A activity, key regulatory approvals, and notable pipeline developments shaped the global pharma landscape. Meanwhile, pricing decisions and policy shifts continue to influence market dynamics and strategic positioning. M&A and Strategic Deals Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05B expands its footprint in the metabolic disease space. Read more → Biogen’s partnership with Dayra aims to enhance its immunological disease portfolio, indicating a strategic focus on immune-mediated conditions. Read more → Regulatory and Approvals Otsuka secured FDA approval for Voyxact in kidney disease, marking a significant step…